Radiopharmaceutical Formulation and Preclinical Testing of ⁶⁸Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial

The new minigastrin analog DOTA-MGS5 is a promising new candidate for targeting cholecystokinin-2 receptor (CCK2R)-expressing tumors. To enable the clinical translation of PET/CT imaging using ⁶⁸Ga-labeled DOTA-MGS5, different quality and safety aspects need to be considered to comply wit...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Anton A. Hörmann, Maximilian Klingler, Christine Rangger, Christian Mair, Clemens Decristoforo, Christian Uprimny, Irene J. Virgolini, Elisabeth von Guggenberg
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2021-06-01
Edice:	Pharmaceuticals
Témata:	cholecystokinin-2 receptor minigastrin molecular imaging radiometals clinical trial automated synthesis
On-line přístup:	https://www.mdpi.com/1424-8247/14/6/575
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!